Caris Life Sciences, Inc.（CAI）财务数据CAICaris Life Sciences, Inc.

Evaluating the bottom line, Caris Life Sciences, Inc. maintains a gross margin of 68.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 10.21%, while the net margin is -0.24%. These profitability ratios, combined with a Return on Equity (ROE) of 20.13%, provide a clear picture of how effectively CAI converts its operational activities into shareholder value.

In the context of the broader market, CAI competes directly with industry leaders such as AXSM and ARWR. With a market capitalization of $8.39B, it holds a significant position in the sector. When comparing efficiency, CAI's gross margin of 68.10% stands against AXSM's 93.06% and ARWR's 100.00%. Such benchmarking helps identify whether Caris Life Sciences, Inc. is trading at a premium or discount relative to its financial performance.

Caris Life Sciences has demonstrated strong revenue growth, with Q2 2026 revenue at $263.7 million, a 45% year-over-year increase. The gross margin has also improved significantly, reaching 75.43% in Q4 2025, indicating effective cost management and pricing power.